University of Maryland School of Medicine logo
Emergency Medicine
All Departments
UMSOM Assistant
UMEM Educational Pearls
  • Home
  • Departments
  • Emergency Medicine
  • CME
  • UMEM Educational Pearls
  • CME
  • Courses and Conferences
  • Free Open Access Medical Education
  • UMEM Educational Pearls

Search

1-2 of 2 results by Jill Logan


Title: Levofloxacin dosing for CAP

Category: Pharmacology & Therapeutics

Keywords: Levofloxacin, duration, dose, CAP, pneumonia (PubMed Search)

Posted: 7/1/2017 by Jill Logan (Updated: 7/21/2026)

When you look up dosing for levofloxacin for community acquired pneumonia (CAP), you will find that both of the following options are approved:

  • Levofloxacin 500 mg IV/PO daily x 7-14 days
  • Levofloxacin 750 mg IV/PO daily x 5 days

This is based on a multicenter, randomized, double-blind, active treatment trial comparing these two regimens in CAP (mild to severe). This non-inferiority trial shows that the 750 mg dose of levofloxacin for 5 days is "at least as effective and well tolerated" as the 500 mg dose of levofloxacin for 10 days.

So why should you choose the 750 mg daily x 5 day regimen?

  • Higher doses maximize the concentration-dependent pharmacokinetic profile of the drug
  • Higher doses and shorter duration may be associated with less drug resistance
  • Patients subjectively report feeling better at day 3 with the higher dose regimen

As alway with levofloxacin, don't forget to renally dose adjust subsequent doses when writting a script or scheduled inpatient order for patients with reduced creatinine clearance! 

Show Additional Information

Show References

Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm. Clin Infect Dis. 2003;37:752-60.



Title: S.aureus in the urine and the risk for bacteremia

Category: Pharmacology & Therapeutics

Keywords: MSSA, MRSA, bacturia, bacteremia, Staph aureus, Staphlococcus aureus (PubMed Search)

Posted: 6/4/2017 by Jill Logan (Updated: 7/21/2026)

  • The incidence of Staphylococcus aurea as a urinary pathogen is increasing, however, this finding may represent more than a simple urinary tract infection.
  • One review found an 8-21%rate of association between S. aureus in the urine with bacteremia.
  • Additional work up, including blood cultures, may be warranted in patients with systemic symptoms, lack of access to follow up, and no urinary tract pathology or instrumentation.

Show Additional Information

Risk factors associated with S. aureus bacturia include:

  • catheterization and/or invasive urologic procedures
  • Urinary obstruction
  • Malignancy
  • Long term care facility residence
  • Recent antibiotics

Show References

Al Mohajer M, Darouiche RO. Staphylococcus aureus bacteriura: source, clinical relevance, and management. Curr Infect Dis Rep. 2012;14:601-6.



University of Maryland School of Medicine logo
  • Departments
  • Programs
  • Research Centers
  • Institutes
  • Graduate Education
  • CIBR Cores
  • Offices of the Dean
    • University of Maryland, Baltimore
    • University of Maryland Medical Center
    • Medical Alumni Association of the University of Maryland
    • Health Sciences and Human Services Library
University of Maryland School of Medicine
655 W. Baltimore Street
Baltimore, MD 21201
Contact Us

© University of Maryland School of Medicine

    • Webmaster
    • Web Accessibility
    • Site Index
    • UMB Hotline
    • Employment
    • Map